Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399818 | 0.88 | ALDH1A1 (0.43) | SMN1; SMN2MAPTPOLBGAAROCK2 | |
| SCHEMBL25397933 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPTPOLBGAAROCK2 | |
| SCHEMBL17040325 | 0.82 | ATM (0.47) | SMN1; SMN2MAPTPOLBROCK2TSHR | |
| SCHEMBL25400526 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTPOLBGAAROCK2 | |
| SCHEMBL17037432 | 0.78 | ATM (0.47) | SMN1; SMN2MAPTPOLBROCK2TSHR | |
| SCHEMBL18595228 | 0.77 | ATM (0.44) | SMN1; SMN2MAPTPOLBROCK2TSHR | |
| SCHEMBL25397810 | 0.76 | HTT (0.40) | SMN1; SMN2MAPTPOLBGAATSHR | |
| SCHEMBL13940123 | 0.76 | ALDH1A1 (0.49) | SMN1; SMN2MAPTPOLBTSHRALDH1A1 | |
| SCHEMBL7298281 | 0.75 | ALDH1A1 (0.47) | SMN1; SMN2MAPTGAATSHRHTT | |
| SCHEMBL25398536 | 0.75 | ALDH1A1 (0.47) | SMN1; SMN2MAPTPOLBROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| CN-119278197-A | Imidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | SMN1; SMN2 401/4885MAPT 1789/4885POLB 4558/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | SMN1; SMN2 601/4885MAPT 2025/4885POLB 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.